A Novel Rehabilitation Approach: Dyadic Strategy Training for Stroke Survivors and Their Caregivers
NCT05571150, Not applicable, Unknown, Taipei Medical University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Novel Rehabilitation Approach: Dyadic Strategy Training for Stroke Survivors and Their Caregivers | ClinicalTrials.gov |
| NCT number | NCT05571150 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 138 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Taipei Medical University | ClinicalTrials.gov |
| Conditions | Stroke | ClinicalTrials.gov |
| Interventions | Dyad-focused strategy training intervention, Attention-control intervention | ClinicalTrials.gov |
| First posted | 2022-10-07 | ClinicalTrials.gov |
| Last updated | 2024-07-03 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Participation Measure- 3 Domains, 4 Dimensions (PM-3D4D) | From baseline to up to 6 weeks | The PM-3D4D is a 24-item measure that was designed to evaluate three domains of participation: Productivity, Social, and Community. | ClinicalTrials.gov |
| Secondary | World Health Organization Quality of Life (WHOQOL-Brief) | From baseline to up to 6 weeks | The WHOQOL-BREF (Taiwan ver.) is a self-administered questionnaire comprising 28 questions on individuals' perceptions of their health and well-being over the previous two weeks. Responses to questions are on a 1-5 Likert scale where 1 represents "disagree" or "not at all" and 5 represents "completely agree" or "extremely". | ClinicalTrials.gov |
| Secondary | World Health Organization Quality of Life (WHOQOL-Brief) | From baseline to up to 18 weeks | The WHOQOL-BREF (Taiwan ver.) is a self-administered questionnaire comprising 28 questions on individuals' perceptions of their health and well-being over the previous two weeks. Responses to questions are on a 1-5 Likert scale where 1 represents "disagree" or "not at all" and 5 represents "completely agree" or "extremely". | ClinicalTrials.gov |
| Secondary | World Health Organization Quality of Life (WHOQOL-Brief) | From baseline to up to 30 weeks | The WHOQOL-BREF (Taiwan ver.) is a self-administered questionnaire comprising 28 questions on individuals' perceptions of their health and well-being over the previous two weeks. Responses to questions are on a 1-5 Likert scale where 1 represents "disagree" or "not at all" and 5 represents "completely agree" or "extremely". | ClinicalTrials.gov |
| Secondary | General Self-Efficacy Scale (GSES) | From baseline to up to 6 weeks | The GSES, sometimes seen as GSE, is a 10-item psychometric scale created to assess perceived self-efficacy regarding coping and adaptation abilities in daily activities and isolated stressful events. Responses to questions are on a 1-4 Likert scale where 1 represents "Not at all true" and 4 represents "Exactly true." | ClinicalTrials.gov |
| Secondary | General Self-Efficacy Scale (GSES) | From baseline to up to 18 weeks | The GSES, sometimes seen as GSE, is a 10-item psychometric scale created to assess perceived self-efficacy regarding coping and adaptation abilities in daily activities and isolated stressful events. Responses to questions are on a 1-4 Likert scale where 1 represents "Not at all true" and 4 represents "Exactly true." | ClinicalTrials.gov |
| Secondary | General Self-Efficacy Scale (GSES) | From baseline to up to 30 weeks | The GSES, sometimes seen as GSE, is a 10-item psychometric scale created to assess perceived self-efficacy regarding coping and adaptation abilities in daily activities and isolated stressful events. Responses to questions are on a 1-4 Likert scale where 1 represents "Not at all true" and 4 represents "Exactly true." | ClinicalTrials.gov |
| Secondary | Activity Measure for Post-Acute Care (AM-PAC) Short Forms | From baseline to up to 6 weeks | The AM-PAC consists of three subscales that assess three activity domains: basic mobility, daily activity, and applied cognitive. The inpatient short consists of 6 items per domain, and the outpatient short consists of 15-19 per domain. Each item asks the respondent to rate the difficulty of performing specified activities using a 4-point scale. The summary scores for each subscale will be transformed into standardized scores on the t-score scale. | ClinicalTrials.gov |
| Secondary | Activity Measure for Post-Acute Care (AM-PAC) Short Forms | From baseline to up to 18 weeks | The AM-PAC consists of three subscales that assess three activity domains: basic mobility, daily activity, and applied cognitive. The inpatient short consists of 6 items per domain, and the outpatient short consists of 15-19 per domain. Each item asks the respondent to rate the difficulty of performing specified activities using a 4-point scale. The summary scores for each subscale will be transformed into standardized scores on the t-score scale. | ClinicalTrials.gov |
| Secondary | Activity Measure for Post-Acute Care (AM-PAC) Short Forms | From baseline to up to 30 weeks | The AM-PAC consists of three subscales that assess three activity domains: basic mobility, daily activity, and applied cognitive. The inpatient short consists of 6 items per domain, and the outpatient short consists of 15-19 per domain. Each item asks the respondent to rate the difficulty of performing specified activities using a 4-point scale. The summary scores for each subscale will be transformed into standardized scores on the t-score scale. | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment (MoCA) | From baseline to up to 6 weeks | MoCA is a 30-question test. It checks different cognitive or thinking abilities to help people quickly assess a patient's cognitive health. The score ranges from 0 to 30. A score of 26 and higher is considered normal. | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment (MoCA) | From baseline to up to 18 weeks | MoCA is a 30-question test. It checks different cognitive or thinking abilities to help people quickly assess a patient's cognitive health. The score ranges from 0 to 30. A score of 26 and higher is considered normal. | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment (MoCA) | From baseline to up to 30 weeks | MoCA is a 30-question test. It checks different cognitive or thinking abilities to help people quickly assess a patient's cognitive health. The score ranges from 0 to 30. A score of 26 and higher is considered normal. | ClinicalTrials.gov |
| Secondary | Stroop Test | From baseline to up to 6 weeks | The Stroop test assesses the ability to inhibit cognitive interference that occurs when processing a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute. Participants will be asked to read out the word's ink color as accurately as soon as possible. The ink color of the word could be congruent or incongruent with the written color name. Each participant's time to complete the task will be calculated and recorded. | ClinicalTrials.gov |
| Secondary | Stroop Test | From baseline to up to 18 weeks | The Stroop test assesses the ability to inhibit cognitive interference that occurs when processing a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute. Participants will be asked to read out the word's ink color as accurately as soon as possible. The ink color of the word could be congruent or incongruent with the written color name. Each participant's time to complete the task will be calculated and recorded. | ClinicalTrials.gov |
| Secondary | Stroop Test | From baseline to up to 30 weeks | The Stroop test assesses the ability to inhibit cognitive interference that occurs when processing a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute. Participants will be asked to read out the word's ink color as accurately as soon as possible. The ink color of the word could be congruent or incongruent with the written color name. Each participant's time to complete the task will be calculated and recorded. | ClinicalTrials.gov |
| Secondary | TMT Test | From baseline to up to 6 weeks | The TMT test measures sustained attention, sequencing, mental flexibility, and visual tracking. | ClinicalTrials.gov |
| Secondary | TMT Test | From baseline to up to 18 weeks | The TMT test measures sustained attention, sequencing, mental flexibility, and visual tracking. | ClinicalTrials.gov |
| Secondary | TMT Test | From baseline to up to 30 weeks | The TMT test measures sustained attention, sequencing, mental flexibility, and visual tracking. | ClinicalTrials.gov |
| Secondary | Participation Measure- 3 Domains, 4 Dimensions (PM-3D4D) | From baseline to up to 18 weeks | The PM-3D4D is a 24-item measure that was designed to evaluate three domains of participation: Productivity, Social, and Community. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 40398954 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)